CERTCertara, Inc.
The Read
1% rise after missing Q1 2026 earnings but gained 14% in August following a Q2 revenue miss, share repurchase authorization, and leadership changes, with historical partnership catalysts averaging about 12% moves.
The schedule
- Mon5Oct
Market reaction to new FDA guidelines surrounding alternative testing methods and biosimulation.
- Wed14Oct
Expected presentation detailing proprietary updates to the Simcyp biosimulation platform and next-generation AI integrations.
- Mon1Feb
Q3 earnings providing early visibility into 2027 biopharma spending trends and full-year margin trajectories.
- Wed28Apr
Year-end financial results determining the success of the 2026 strategic reset and establishing the foundational 2027 baseline.
- Mon10May
First quarter results offering early indicators of sales execution and pipeline conversion in the new fiscal year.
Past
- Tue1Sep
Assessment of client renewal cycles and biopharma software budget commitments for the upcoming fiscal year.
- Wed5Aug
Actual outcome: Bull · $8.13 at outcome
Certara reported Q2 revenue of $93.3 million, up 1% year-over-year, and missed EPS estimates, but management reaffirmed its full-year revenue guidance. Despite the earnings miss, the stock rallied past the $8.00 bull target, driven by the authorization of an additional $50 million share repurchase program, strategic cost structure changes, and the appointment of a new Chief Commercial Officer.
Quarterly earnings report evaluating whether Certara can reverse sluggish 1% YoY revenue growth and negative net income trends.
- Mon11May
Actual outcome: Mixed · $5.21 at outcome
Certara reported Q1 2026 revenue of $106.9 million, up just 1% year-over-year, and missed consensus EPS estimates ($0.09 vs. $0.11 expected). Although the company outlined a strategic reset and updated guidance to reflect a recent divestiture, the combination of soft services results and multiple shareholder investigations kept the market's reaction muted. Consequently, shares experienced a minor 2.1% increase, remaining ambiguous and hovering near the $5.10 bear floor.
Q1 2026 results and a full-year 2026 guidance update will be the first checkpoint on whether Certara can re-accelerate beyond low-single-digit revenue growth while stabilizing margins, with the stock compressed near its 52-week low at $5.79.
